

Gene Therapy Readiness Checklist.

Key Payer considerations for proactively preparing and planning for the rising availability of Gene Therapy treatments.



Benefit Assessment

- Does current therapy alignment match the plan's intent?
 - Medical vs. Pharmacy
- Is coverage duplicative?
 - Same therapies covered on both the medical and pharmacy benefit
 - Best suited for coverage under medical
- Are all currently FDA-approved gene therapies covered under the benefit?
 - If not, does that match the plan's intent for coverage?



Contract Assessment

- Request walkthrough with current vendor(s) to discuss contract details and reimbursement related to gene therapies
 - How are gene therapies being reimbursed?
 - Rates: by individual therapy or at the gene therapy class level?
 - How are ancillary/professional services reimbursed under the medical benefit: by service or global case rate?



Clinical Assessment

- Are prior authorizations in place for all covered therapies to confirm clinical appropriateness of use?
 - Do the criteria match the approved FDA label for use of any given therapy?
 - Off-label use should not have a pathway for approval
- Are prior authorizations in place for anticipated ancillary services associated with any given therapy?
 - Including but not limited to administration, adjunct procedures/medications, Inpatient or Outpatient services



Notification Process

- What is your preference for being notified regarding new gene therapy claimants?
 - Established utilization reviews vs. custom process
- If a custom process is desired, consider a starting point and ongoing cadence with your vendor(s)
 - PA approval, with a look back of every X days



Management & Monitoring Assessment

- What happens to the member following medication administration?
 - Confirm if case management is a part of the ongoing care plan
 - What is the frequency and duration of interactions?
 - Is reporting available?
- Does your vendor have policies in place for outcomes monitoring and reporting, following therapy?



Affordability /Risk Assessment

- What is the likelihood your plan may experience gene therapy utilization?
- Have you evaluated the financial impact to your plan, as a result of gene therapy utilization?
- Keeping in mind your plan's budget and current contractual pricing terms, are you content with the risk vs affordability continuum should your plan experience gene therapy claim(s)?

OUR PROPRIETARY TECHNOLOGY AND UNMATCHED EXPERTISE WORK FOR YOU

Truveris is a leading digital health company focused on delivering objective truth and clarity in pharmacy. Truveris' proprietary technology, coupled with pharmacy expertise, brings transparency across the entire pharmacy chain. Our solutions provide the knowledge required to compare, manage, and optimize costs and benefits for organizations and their workers, helping them lead healthier, more productive lives. For more information about our pharmacy solutions and to speak with a representative, please contact us at: info@truveris.com